Inotuzumab ozogamicin has shown extremely promising results in clinical trials for treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). There are, however, still issues with legislation in several EU countries which prevent its widespread use, as David Marks, MBBS, PhD, FRACP, FRCPath, of University Hospitals Bristol NHS Foundation Trust, Bristol, UK, explains at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. Prof. Marks speaks about future goals for inotuzumab therapy, and discusses the trials that are needed to establish this treatment.
